NAD+ · Research brief

NAD+ Blood Work Labs Check Before After — What to Measure

Q: Can I use a standard blood test to check NAD+ levels?

No — standard blood chemistry panels do not include NAD+ measurement, and most commercial labs lack the specialised equipment and protocols required for valid intracellular NAD+ testing. Serum or plasma NAD+ tests are available through some direct-to-consumer lab companies, but these measure circulating NAD+, which does not reflect intracellular concentrations. Proper NAD+ testing requires PBMC isolation, cell lysis, and enzymatic assay or LC-MS analysis — services offered by specialty metabolomics labs like Jinfiniti Precision Medicine. Without intracellular measurement and the NAD+/NADH ratio, you’re getting data that doesn’t predict cellular function.

Q: What does a low NAD+/NADH ratio indicate?

A low NAD+/NADH ratio (below 3:1) indicates redox imbalance, with excessive NADH accumulation relative to NAD+. This typically reflects impaired mitochondrial electron transport chain function — NADH is being generated through glycolysis and the citric acid cycle but isn’t being oxidised efficiently in the respiratory chain. Common causes include complex I deficiency, CoQ10 depletion, mitochondrial DNA mutations, or inflammatory conditions that impair oxidative phosphorylation. Functionally, a collapsed ratio predicts poor cellular energy production, increased oxidative stress, and metabolic inflexibility regardless of total NAD+ levels.

Q: How much does intracellular NAD+ testing cost?

Intracellular NAD+ testing through specialty metabolomics labs typically costs $300–600 per panel, depending on which biomarkers are included. A comprehensive before-and-after NAD+ panel including intracellular NAD+/NADH in PBMCs, oxidative stress markers, and mitochondrial enzyme activity generally costs $400–800 total across two time points (baseline and 8–12 week follow-up). This is significantly more expensive than standard blood work because it requires fresh specimen processing, cell isolation, and specialised enzymatic or mass spectrometry analysis. Most insurance does not cover these panels when ordered for wellness or longevity purposes rather than specific diagnosed conditions.

Q: What other biomarkers should I track alongside NAD+ levels?

Track oxidative stress markers (8-OHdG for DNA damage, F2-isoprostanes for lipid peroxidation), mitochondrial enzyme activity (citrate synthase as a proxy for mitochondrial density, complex I activity for electron transport function), and systemic inflammation markers (hsCRP, IL-6). These functional biomarkers reveal whether NAD+ repletion is translating into improved cellular bioenergetics and reduced oxidative stress. Without them, you cannot distinguish between NAD+ increases that drive metabolic improvements versus increases that remain metabolically inert due to downstream blocks. Fasting glucose, HbA1c, and triglycerides are useful secondary markers — NAD+ repletion typically improves insulin sensitivity and lipid metabolism over 12 weeks.

Q: Why did my NAD+ levels not increase despite taking NR or NMN supplements?

Poor response to NAD+ precursor supplementation (less than 20% intracellular NAD+ increase) most commonly results from high CD38 enzyme activity, which degrades NAD+ as rapidly as it’s synthesised. Chronic inflammation, autoimmune conditions, and ageing all upregulate CD38 on immune cells. Other causes include impaired nicotinamide riboside kinase (NRK) expression, methylation deficits that limit NAD+ salvage pathway flux, or genetic polymorphisms in NAMPT or NMNAT enzymes. Addressing underlying inflammation with diet, omega-3 fatty acids, or anti-inflammatory peptides often restores NAD+ response. Some patients require CD38 inhibitors (apigenin, quercetin) or alternative NAD+ precursors.

Q: Is NAD+ testing necessary before starting NAD+ supplementation?

Baseline NAD+ testing is not strictly necessary to begin supplementation, but it’s the only way to objectively confirm response and guide dosing. Without baseline intracellular NAD+ and NAD+/NADH ratio measurements, you cannot distinguish between responders and non-responders or identify when supplementation is ineffective due to high CD38 activity or downstream metabolic blocks. For patients with significant health investment in NAD+ protocols — particularly those using IV NAD+ or high-dose precursors — baseline and follow-up testing at 8–12 weeks provides critical data that subjective assessment cannot. Tracking clinical outcomes (energy, recovery, cognition) is a reasonable alternative when testing cost is prohibitive.

Q: What is the best time of day to draw blood for NAD+ testing?

Draw blood for NAD+ testing in the morning after an overnight fast (8–12 hours), ideally between 7–9 AM to control for circadian variation. NAD+ metabolism follows a diurnal rhythm, with levels peaking in the early morning and declining throughout the day in response to feeding, activity, and metabolic demand. Drawing labs at the same time of day and fasting status for baseline and follow-up tests is critical — a fed sample versus fasted sample can produce 20–30% variation in intracellular NAD+ concentrations. Avoid exercise, caffeine, and alcohol for 24 hours before testing, as all acutely affect NAD+ metabolism.

Q: Can high inflammation prevent NAD+ levels from increasing?

Yes — chronic inflammation drives CD38 enzyme expression on immune cells, which consumes NAD+ to produce cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP), both involved in calcium signalling. High baseline hsCRP (above 3.0 mg/L) or IL-6 (above 5 pg/mL) predicts poor NAD+ response to supplementation because CD38 degrades NAD+ as rapidly as NR or NMN generates it. Addressing inflammation first — through diet modification, omega-3 fatty acids (2–4 g EPA/DHA daily), curcumin, or anti-inflammatory peptides — often restores NAD+ response within 4–8 weeks. Retesting inflammatory markers alongside NAD+ reveals whether inflammation management is succeeding.

Real Peptides Research TeamEditorial

Updated May 1, 20268 min read

56 WORDS

Short answer

Research from Harvard Medical School found that serum NAD+ measurements correlate poorly with intracellular NAD+ status. The metric that actually predicts cellular energy production and metabolic function. Most commercial panels measure total circulating NAD+, which fluctuates based on recent meals, hydration status, and time of day, making before-and-after comparisons nearly meaningless without controlling for collection variables.

Key takeaways

Serum NAD+ levels do not reflect intracellular NAD+ status. The only meaningful measurement requires isolated PBMCs analysed via enzymatic assay or LC-MS, not standard blood chemistry panels.
The NAD+/NADH ratio is the most functionally relevant biomarker. Total NAD+ can be normal while the ratio collapses due to NADH accumulation from impaired electron transport.
Baseline testing before NAD+ supplementation must include intracellular NAD+/NADH, oxidative stress markers (8-OHdG, F2-isoprostanes), mitochondrial enzyme activity (citrate synthase, complex I), and inflammatory markers (hsCRP, IL-6).
Expected intracellular NAD+ increases after 8–12 weeks of NR or NMN supplementation range from 50–100%, with the NAD+/NADH ratio rising by 1.5–2× baseline in responders.
Patients showing NAD+ increases without functional improvements (reduced oxidative stress, improved mitochondrial markers) likely have downstream metabolic blocks. Insulin resistance, thyroid dysfunction, or impaired fatty acid oxidation. That prevent NAD+ from driving cellular bioenergetics.
Lab timing and collection conditions critically affect results. Draw follow-up labs at the same time of day and fasting status as baseline to control for diurnal and postprandial NAD+ fluctuations.

We've worked with researchers who've reviewed hundreds of NAD+ lab panels submitted by patients attempting to track supplementation efficacy. The single biggest gap: almost no one is measuring the NAD+/NADH ratio, the functional biomarker that reflects redox balance and mitochondrial respiratory capacity.

What does a proper NAD+ blood work panel measure before and after supplementation?

A comprehensive NAD+ monitoring panel includes intracellular NAD+ and NADH concentrations measured in isolated peripheral blood mononuclear cells (PBMCs), the NAD+/NADH ratio, plasma markers of oxidative stress (8-OHdG, F2-isoprostanes), mitochondrial enzyme activity (citrate synthase, complex I), and inflammatory markers (hsCRP, IL-6). Serum NAD+ alone is insufficient. Functional metabolic markers reveal whether NAD+ repletion is translating into improved cellular bioenergetics.

Why Standard NAD+ Lab Panels Miss the Point

Most commercially available NAD+ tests measure total NAD+ in serum or plasma. The fluid component of blood after cells are removed. The problem: NAD+ is a charged molecule that doesn't cross cell membranes freely, meaning circulating levels don't reflect what's happening inside cells where NAD+-dependent enzymes (sirtuins, PARPs, CD38) actually function.

Intracellular NAD+ concentrations in muscle, liver, or brain tissue can be 10–100× higher than serum levels. A patient supplementing with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) can show no change in serum NAD+ while intracellular concentrations rise significantly. The inverse is also true. Serum testing alone creates false negatives and false positives.

The NAD+/NADH ratio is the critical functional metric. NAD+ (the oxidised form) accepts electrons during glycolysis and the citric acid cycle, converting to NADH (the reduced form), which then donates those electrons in the mitochondrial electron transport chain. A high NAD+/NADH ratio indicates active oxidative metabolism and preserved mitochondrial function. A declining ratio signals metabolic stress, redox imbalance, or mitochondrial dysfunction. You can have normal total NAD+ but a collapsed ratio if NADH accumulates because electron transport is impaired.

The Baseline Panel — What to Test Before Starting NAD+ Therapy

Before beginning any NAD+ supplementation protocol, establish baseline measurements across four domains: intracellular NAD+ metabolism, oxidative stress, mitochondrial function, and systemic inflammation. Without baseline data, you cannot distinguish treatment effects from normal biological variation.

Intracellular NAD+ and NADH in PBMCs: Peripheral blood mononuclear cells (lymphocytes and monocytes) are isolated from whole blood via density gradient centrifugation, then lysed to measure NAD+ and NADH concentrations using enzymatic cycling assays or liquid chromatography-mass spectrometry (LC-MS). This gives you actual intracellular concentrations. Not plasma levels. The NAD+/NADH ratio is calculated from these values. Standard range for healthy adults: NAD+/NADH ratio between 3:1 and 10:1, with higher ratios indicating more oxidised (metabolically active) states.

Oxidative stress biomarkers: 8-hydroxy-2'-deoxyguanosine (8-OHdG) measures oxidative DNA damage; F2-isoprostanes measure lipid peroxidation; malondialdehyde (MDA) reflects free radical activity. NAD+ supports antioxidant pathways through NADPH generation via the pentose phosphate pathway. Effective NAD+ repletion should reduce these markers over 8–12 weeks.

Mitochondrial enzyme activity: Citrate synthase activity in PBMCs serves as a proxy for mitochondrial density; complex I activity (NADH:ubiquinone oxidoreductase) reflects electron transport chain function. These are functional assays performed on fresh or flash-frozen cell lysates. They degrade rapidly, so specimen handling is critical.

Inflammatory markers: High-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) track systemic inflammation. Chronic inflammation activates CD38, an NAD+-consuming enzyme on immune cells, which depletes cellular NAD+ pools. Reducing inflammation should preserve NAD+ levels. Tracking these markers reveals whether inflammation is confounding your NAD+ response.

The Follow-Up Panel — What Changes to Expect After 8–12 Weeks

Repeat the same panel after 8–12 weeks of consistent NAD+ supplementation (typically 250–500 mg NR or NMN daily, or 500–1000 mg NAD+ IV monthly). Collection timing matters. Draw labs at the same time of day, in the same fasted or fed state, to control for diurnal variation and postprandial shifts in NAD+ metabolism.

Expected intracellular NAD+ changes: Research published in Nature Communications (2018) showed that 1000 mg daily NR increased intracellular NAD+ in PBMCs by 60% at 4 weeks and 90% at 8 weeks, with the NAD+/NADH ratio rising from a baseline mean of 5.2 to 7.8. Not everyone responds identically. Poor responders (≤20% NAD+ increase) may have high baseline CD38 activity, impaired NR kinase expression, or concurrent methylation deficits that limit NAD+ salvage pathway flux.

Oxidative stress marker reductions: Effective NAD+ repletion typically reduces 8-OHdG by 15–30% and F2-isoprostanes by 10–25% over 12 weeks. If oxidative stress markers don't decline, either NAD+ isn't reaching target tissues, antioxidant enzyme expression is impaired, or oxidative load exceeds the capacity of NAD+-dependent defences. All of which warrant further investigation.

Mitochondrial function improvements: Citrate synthase activity may increase modestly (10–20%) with sustained NAD+ elevation, reflecting mitochondrial biogenesis stimulated by SIRT1 activation of PGC-1α. Complex I activity improvements are less consistent. Some patients show 20–40% increases, others show no change. This variability likely reflects genetic differences in mitochondrial DNA copy number and baseline mitochondrial health.

Our team has found that patients who show robust NAD+ increases but no functional biomarker improvements often have downstream metabolic blocks. Impaired fatty acid oxidation, thyroid dysfunction, or insulin resistance. That prevent NAD+ repletion from translating into improved energy metabolism. NAD+ is necessary but not sufficient for metabolic restoration.

NAD+ Blood Work Labs Check Before After: Lab Comparison

Lab Test	Baseline Expected Range	Post-Treatment Target (8–12 weeks)	Interpretation	Clinical Significance
Intracellular NAD+ (PBMCs)	200–400 pmol/million cells	300–600 pmol/million cells (50–100% increase)	≥50% increase = good response; <20% increase = poor response or high CD38 activity	Primary efficacy marker. Measures actual NAD+ repletion
NAD+/NADH Ratio	3:1 to 10:1	6:1 to 12:1 (increase of 1.5–2× baseline)	Higher ratio = improved redox balance and mitochondrial oxidative capacity	Functional marker. More predictive of metabolic health than total NAD+
8-OHdG (oxidative DNA damage)	<15 ng/mg creatinine (urine) or <5 ng/mL (serum)	15–30% reduction from baseline	Reduction indicates NAD+ is supporting antioxidant pathways; no change suggests oxidative load exceeds defence capacity	Reflects NAD+-dependent NADPH generation for glutathione recycling
Citrate Synthase Activity	50–150 nmol/min/mg protein	10–20% increase (modest)	Increase indicates mitochondrial biogenesis via SIRT1/PGC-1α pathway	Proxy for mitochondrial mass. Gradual increases expected over months
hsCRP (inflammation)	<1.0 mg/L (low risk); 1.0–3.0 mg/L (moderate)	Reduction toward <1.0 mg/L	Inflammation activates CD38, depleting NAD+. Reduction preserves NAD+ pools	High baseline hsCRP predicts poor NAD+ response unless inflammation is addressed

What If: NAD+ Lab Testing Scenarios

What If My Intracellular NAD+ Increased But I Feel No Different?

Measure downstream functional markers. If NAD+ rose but citrate synthase activity, complex I activity, and oxidative stress markers didn't improve, NAD+ repletion isn't translating into mitochondrial bioenergetics. Common causes: impaired thyroid function (low T3 suppresses mitochondrial gene expression), insulin resistance (blocks fatty acid oxidation despite adequate NAD+), or genetic polymorphisms in NAMPT or NMNAT enzymes that limit NAD+ utilisation. Adding CoQ10 (200–400 mg daily) and acetyl-L-carnitine (1000–2000 mg daily) often unlocks NAD+-driven energy improvements by supporting electron transport and substrate delivery.

What If My NAD+/NADH Ratio Declined Despite NAD+ Supplementation?

A declining NAD+/NADH ratio despite rising total NAD+ suggests NADH is accumulating faster than it's being oxidised. A sign of impaired electron transport chain function. Possible causes: complex I deficiency, CoQ10 depletion, or mitochondrial DNA mutations. This pattern is common in chronic fatigue syndrome and fibromyalgia patients. Mitochondrial support nutrients (CoQ10, alpha-lipoic acid, PQQ) and aerobic exercise to stimulate mitochondrial biogenesis often restore the ratio over 12–16 weeks.

What If My Baseline NAD+ Was Already High?

High baseline intracellular NAD+ (>500 pmol/million cells) with normal or low NAD+/NADH ratios suggests NAD+ synthesis is functioning but utilisation is impaired. Either because NAD+-consuming enzymes (sirtuins, PARPs) are underactive, or NADH oxidation is blocked. Further supplementation is unlikely to help. Focus instead on stimulating sirtuin activity (resveratrol 500 mg daily, caloric restriction, HIIT exercise) or improving electron transport (CoQ10, mitochondrial-targeted antioxidants like MitoQ).

The Blunt Truth About NAD+ Blood Testing

Here's the honest answer: most NAD+ lab panels sold to consumers are measuring the wrong thing and providing data that's functionally useless. Serum NAD+ is not a valid surrogate for intracellular NAD+ status. The correlation is weak to non-existent because NAD+ doesn't equilibrate across cellular membranes. Testing serum NAD+ before and after supplementation tells you almost nothing about whether the compound reached your cells or improved metabolic function.

The only valid approach is intracellular NAD+ measurement in PBMCs, paired with the NAD+/NADH ratio and downstream functional markers (oxidative stress, mitochondrial enzyme activity). These tests are not available through standard commercial labs. They require specialty labs with expertise in metabolomics and fresh specimen handling. Platforms like Jinfiniti Precision Medicine and select research-affiliated labs offer validated intracellular NAD+ panels, but they're not cheap (typically $300–600 per panel).

If cost is prohibitive, tracking clinical outcomes (energy levels, exercise recovery, cognitive clarity) alongside indirect biomarkers (fasting glucose, HbA1c, lipid panel, hsCRP) over 12 weeks provides more actionable data than a single serum NAD+ measurement. NAD+ repletion improves insulin sensitivity, reduces inflammation, and lowers triglycerides. If those markers don't improve, NAD+ supplementation isn't working regardless of what a serum test shows.

How NAD+ Metabolism Connects to Peptide Research

NAD+ biosynthesis and utilisation are central to cellular stress resilience, mitochondrial function, and longevity. Mechanisms that intersect with peptide-based research compounds. For researchers investigating metabolic and neuroprotective peptides, understanding NAD+ dynamics provides critical context for interpreting experimental outcomes.

Peptides like Thymalin and Cerebrolysin have demonstrated neuroprotective and immune-modulating effects in preclinical models. Pathways that rely heavily on NAD+-dependent enzymes. Real Peptides supplies research-grade peptides synthesised under strict amino-acid sequencing protocols, ensuring consistency across experimental batches for labs investigating these interactions.

Mitochondrial function research often incorporates compounds like MK 677 (a ghrelin mimetic) and Dihexa (a cognitive enhancer), both of which operate in cellular environments where NAD+/NADH balance critically affects outcomes. Researchers tracking NAD+ biomarkers alongside peptide administration can better isolate compound-specific effects from baseline metabolic variation.

NAD+ testing before and after peptide protocols provides mechanistic insight. Whether a compound is working through NAD+-dependent pathways, compensating for NAD+ depletion, or functioning independently. For labs conducting metabolic research, combining intracellular NAD+ panels with peptide experimentation reveals deeper biological interactions than either approach alone. Explore the full range of research peptides and metabolic tools at Real Peptides.

NAD+ blood work done right requires precision, proper specimen handling, and interpretation within a broader metabolic context. Without measuring intracellular concentrations, functional ratios, and downstream biomarkers, you're collecting data points that don't connect to anything meaningful. The difference between effective NAD+ monitoring and expensive guesswork comes down to testing what actually matters. Not what's easiest to measure.

This information is for educational and research purposes. Lab testing protocols, biomarker interpretation, and supplementation decisions should be made in consultation with a licensed healthcare provider familiar with NAD+ metabolism and functional medicine.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The most accurate method is intracellular NAD+ and NADH measurement in peripheral blood mononuclear cells (PBMCs) isolated from whole blood, analysed via enzymatic cycling assay or liquid chromatography-mass spectrometry (LC-MS). This measures actual cellular NAD+ concentrations — not serum levels, which correlate poorly with intracellular status. The NAD+/NADH ratio calculated from these values is the most functionally relevant biomarker, reflecting redox balance and mitochondrial oxidative capacity. Serum NAD+ testing alone is insufficient because NAD+ doesn’t freely cross cell membranes, meaning circulating levels don’t reflect intracellular concentrations where NAD+-dependent enzymes function.

Intracellular NAD+ levels typically rise within 2–4 weeks of consistent NR or NMN supplementation at therapeutic doses (250–500 mg daily), with peak increases observed at 8–12 weeks. A 2018 study in Nature Communications found 1000 mg daily NR increased PBMC NAD+ by 60% at 4 weeks and 90% at 8 weeks. Individual response varies significantly — some patients show minimal increases (<20%) despite compliance, often due to high CD38 activity, impaired NR kinase expression, or methylation deficits. Follow-up lab testing at 8–12 weeks is essential to confirm response and guide dose adjustment.